Insmed’s ‘Ginormous’ Lung Drug Sales; J&J’s US Pricing Deal

Insmed’s ‘ginormous’ lung drug sales; J&J’s US pricing deal

Insmed’s Brinsupri blew past consensus estimates in its first full quarter on the market. Elsewhere, J&J inked pharma’s latest deal with the Trump administration and Madrigal licensed a Pfizer drug.

J&J Agreement Brings 15 of 17 Pharma Companies Into Trump's Drug-Pricing Effort

Johnson & Johnson partners with the Trump Administration to lower drug prices and utilize TrumpR, joining a growing list of pharmaceutical companies.

Johnson & Johnson Joins TrumpRx to Lower Drug Prices, Secures Tariff Exemption

The pharma giant becomes the latest manufacturer to participate in the Trump Administration’s direct-to-patient pricing platform, aligning US drug costs with European benchmarks while reinforcing its domestic manufacturing investments.

J&J strikes drug pricing, tariff deal with the White House

Johnson & Johnson is the latest drugmaker to reach a "most favored nation" deal with the White House, agreeing to lower drug prices in the US in exchange for a reprieve from pharma tariffs. ...